Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial

Authors	VERMA Subodh LUDKA Ondřej DHINGRA Nitish K BUTLER Javed ANKER Stefan D FERREIRA Joao Pedro FILIPPATOS Gerasimos JANUZZI James L LAM Carolyn S P SATTAR Naveed PEIL Barbara NORDABY Matias BRUECKMANN Martina POCOCK Stuart J ZANNAD Faiez PACKER Milton
Year of publication	2022
Type	Article in Periodical
Magazine / Source	LANCET DIABETES & ENDOCRINOLOGY
MU Faculty or unit	Faculty of Medicine
Citation
Doi	http://dx.doi.org/10.1016/S2213-8587(21)00292-8